Breaking News
Exscientia
About Exscientia
At the forefront of small molecule drug discovery
We are the first company to automate drug design, surpassing conventional human endeavour.
Our AI driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters.
With better information to hand than any researcher could acquire individually, our knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, ADME and other key criteria. From this, a selection of the best, information-rich compounds are selected for synthesis and assay.
With new experimental data generated, the results are integrated and the next design cycle initiated. Rapid design-make-test cycles ensure unparalleled progress towards desired project goals.
Exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.
Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical Stage
May 16 2023
Exscientia today announced that Sumitomo Pharma plans to initiate a Phase 1 clinical study of […]
Exscientia Receives First CTA Approval to Initiate IGNITE-AI, a Phase 1/2 Trial of EXS-21546 in Patients with Advanced Solid Tumours
November 28 2022
Exscientia has announced clinical trial application (CTA) approval of IGNITE-AI, enabling site activation in its […]
Exscientia Builds Automated Laboratories in Oxford to Expand Pipeline
August 4 2021
Exscientia today announced the opening of a 21,000 square foot expansion of its facilities at […]
Exscientia Accelerates COVID-19 Drug Discovery Using AI
July 8 2021
Exscientia has received a grant from the Bill & Melinda Gates Foundation and Gates Philanthropy […]
EQRx and Exscientia Enter Strategic Drug Creation, Development, and Commercialization Collaboration to Accelerate the Advancement of New World-Class Medicines
June 25 2021
EQRx, a company committed to developing and delivering important new medicines to patients at radically […]
Exscientia Announces Second Molecule Created Using AI from Sumitomo Dainippon Pharma Collaboration to Enter Phase 1 Clinical Trial
May 13 2021
Exscientia Ltd. (Headquarters: Oxford, UK; CEO: Andrew Hopkins) is pleased to acknowledge that Sumitomo Dainippon Pharma Co., […]
Exscientia Announces First AI-Designed Immuno-Oncology Drug to Enter Clinical Trials
April 9 2021
Exscientia, a leading artificial intelligence (AI)-driven pharmatech company, today announced the first AI-designed molecule for […]